Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 3 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Roflumilast cream may reduce severity of plaque psoriasis

Audrey Abella
25 Aug 2020

Use of the topical PDE-4* inhibitor roflumilast led to greater reductions in the signs and symptoms of chronic plaque psoriasis compared with placebo, a phase IIb trial has shown.

“[W]e found that roflumilast cream was efficacious in reducing the severity of psoriasis according to an investigator assessment of a state of clear or almost clear of plaque psoriasis (IGA** score of 0 or 1, respectively),” said the researchers.

At 6 weeks, more roflumilast recipients exhibited an IGA score of 0 or 1 vs those on placebo (28 percent vs 8 percent; p<0.001 [0.3% cream] and 23 percent vs 8 percent; p=0.004 [0.15% cream]). These rates increased by week 8 (38 percent [0.3%], 31 percent [0.15%], and 12 percent [placebo]) and week 12 (38, 32, and 16 percent, respectively). [N Engl J Med 2020;383:229-239]

“[Although the] outcomes with the higher concentration of roflumilast … were numerically better than those with the lower dose … no formal comparisons were made between dose levels,” the researchers noted.

Intervention-related adverse events (AEs) were observed in 6 percent and 3 percent of roflumilast 0.3% and 0.15% recipients, respectively. Fewer application-site reactions were noted with the 0.15% vs the 0.3% roflumilast cream (n=1 vs 4).

 

Sensitive areas included

Adults with mild, moderate, or severe chronic plaque psoriasis*** were included in the analysis. A total of 331 participants were randomized 1:1:1 to apply roflumilast 0.3% or 0.15% cream, or a vehicle placebo cream, once daily to all lesions – including sensitive (ie, facial and intertriginous) areas – for 12 weeks.

Among those with mild intertriginous psoriasis (~15 percent), more roflumilast vs placebo recipients achieved an IGA score of 0 or 1, plus a 2-grade improvement in the intertriginous area IGA score (73 percent [0.3%] and 44 percent [0.15%] vs 29 percent [placebo]). By week 12, almost all roflumilast 0.3% recipients in this subgroup (n=14/15) achieved an intertriginous area IGA score of 0 vs three out of 17 placebo recipients.

“Treatment of sensitive areas … with topical agents requires special consideration because of the sensitivity of the skin in these areas as well its thinness – factors that potentially enhance systemic absorption,” said the researchers.

 

Choosing the PDE-4 route

While there are effective topical glucocorticoids for psoriasis, their use is confined to no more than 2–8 weeks, and is associated with gradually resolving or irreversible AEs. [Am Fam Physician 2009;79:135-140; Indian Dermatol Online J 2014;5:416-425] Topical calcineurin inhibitors, which have been used off-label for facial and intertriginous psoriasis, are ineffective in nonfacial sites and has a cancer risk potential. [Arch Dermatol 2005;141:1154]

PDE-4 inhibition downregulates immune modulators#. [Front Pharmacol 2018;9:1048] However, the approved oral PDE-4 inhibitor apremilast is confounded by gastrointestinal (GI) side effects (eg, diarrhoea, nausea), noted the researchers. “[Our findings show that] topical administration of roflumilast cream was associated with an incidence of <1 percent of [GI] events … possibly as a result of bypassing the [GI] tract with topical administration,” they said.

Overall, the findings provide evidence of a topical PDE-4 inhibitor alternative for the treatment of psoriasis, for which no topical PDE-4 inhibitor is approved, noted the researchers. Larger and longer trials are thus warranted to ascertain the safety and durability of response of roflumilast in this setting.

 

 

Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 3 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.